Ultra-Rare Immune System Disease Gets First FDA-Approved Treatment

(MedPage Today) -- The FDA approved pozelimab (Veopoz) as the first treatment for adults and children ages 1 year and up with CD55-deficient protein-losing enteropathy. Also known as CHAPLE (complement hyperactivation, angiopathic thrombosis...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news